Quest Diagnostics Incorporated (DGX) Income Statement Analysis

See more : Updater Services Limited (UDS.BO) Income Statement Analysis – Financial Results

Complete financial analysis of Quest Diagnostics Incorporated (DGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quest Diagnostics Incorporated, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.

You may be interested

Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. (603168.SS) Income Statement Analysis – Financial Results
Local Bounti Corporation (LOCL-WT) Income Statement Analysis – Financial Results
Irving Resources Inc. (IRV.CN) Income Statement Analysis – Financial Results
PT Data Sinergitama Jaya Tbk (ELIT.JK) Income Statement Analysis – Financial Results
EKINOPS S.A. (EKI.PA) Income Statement Analysis – Financial Results

Quest Diagnostics Incorporated (DGX)

Industry: Medical - Diagnostics & Research

Sector: Healthcare

Website: https://www.questdiagnostics.com

About Quest Diagnostics Incorporated

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996
Revenue	9.25B	9.88B	10.79B	9.44B	7.73B	7.53B	7.71B	7.52B	7.49B	7.44B	7.15B	7.38B	7.51B	7.37B	7.46B	7.25B	6.70B	6.27B	5.50B	5.13B	4.74B	4.11B	3.63B	3.42B	2.21B	1.46B	1.53B	1.62B
Cost of Revenue	6.29B	6.45B	6.58B	5.80B	5.04B	4.93B	4.72B	4.62B	4.66B	4.64B	4.33B	4.36B	4.40B	4.32B	4.32B	4.26B	3.97B	3.70B	3.26B	2.99B	2.77B	2.43B	2.15B	1.97B	1.32B	813.90M	875.50M	1.01B
Gross Profit	2.96B	3.43B	4.21B	3.63B	2.69B	2.61B	2.99B	2.90B	2.84B	2.80B	2.82B	3.02B	3.12B	3.05B	3.13B	2.99B	2.74B	2.57B	2.25B	2.14B	1.97B	1.68B	1.48B	1.45B	886.20M	644.70M	653.20M	605.42M
Gross Profit Ratio	32.00%	34.74%	39.02%	38.50%	34.80%	34.59%	38.79%	38.58%	37.85%	37.63%	39.46%	40.88%	41.48%	41.41%	42.03%	41.29%	40.79%	41.04%	40.82%	41.66%	41.57%	40.79%	40.69%	42.49%	40.19%	44.20%	42.73%	37.46%
Research & Development	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	1.42B	1.75B	1.68B	1.68B	1.73B	1.70B	1.75B	1.81B	1.71B	1.75B	1.74B	1.61B	1.43B	1.26B	1.23B	1.17B	1.07B	1.02B	1.00B	643.40M	481.60M	502.10M	495.32M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-15.00K	27.00K	-18.00K	-34.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	1.62B	1.87B	1.73B	1.55B	1.46B	1.42B	1.75B	1.68B	1.68B	1.73B	1.70B	1.75B	1.81B	1.71B	1.75B	1.74B	1.61B	1.43B	1.26B	1.23B	1.17B	1.07B	1.02B	1.00B	643.40M	481.60M	502.10M	495.32M
Other Expenses	0.00	131.00M	101.00M	112.00M	1.00M	-8.00M	16.00M	-48.00M	-143.00M	4.00M	8.00M	6.70M	305.79M	48.47M	27.04M	33.98M	30.87M	10.91M	20.49M	6.70M	8.20M	8.37M	46.11M	134.30M	90.80M	68.80M	76.40M	711.38M
Operating Expenses	1.76B	2.01B	1.83B	1.66B	1.46B	1.50B	1.83B	1.74B	1.77B	1.82B	1.82B	1.82B	2.12B	1.76B	1.77B	1.77B	1.64B	1.44B	1.28B	1.23B	1.17B	1.08B	1.06B	1.14B	734.20M	550.40M	578.50M	1.21B
Cost & Expenses	7.94B	8.46B	8.41B	7.47B	6.50B	6.43B	6.54B	6.36B	6.43B	6.45B	6.15B	6.18B	6.52B	6.07B	6.10B	6.03B	5.61B	5.14B	4.54B	4.23B	3.94B	3.52B	3.22B	3.10B	2.05B	1.36B	1.45B	2.22B
Interest Income	11.00M	10.00M	1.00M	3.00M	5.00M	2.00M	2.00M	1.00M	1.00M	3.00M	3.00M	3.00M	2.77M	1.41M	2.52M	5.71M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	163.00M	138.00M	151.00M	163.00M	175.00M	167.00M	151.00M	143.00M	153.00M	164.00M	159.00M	164.70M	170.60M	146.10M	144.10M	185.48M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	439.00M	437.00M	408.00M	361.00M	329.00M	309.00M	270.00M	249.00M	304.00M	314.00M	283.00M	286.60M	281.10M	254.00M	256.70M	264.60M	237.88M	197.40M	176.12M	168.73M	153.90M	131.39M	147.73M	134.30M	90.80M	68.80M	76.40M	99.10M
EBITDA	1.73B	1.82B	3.16B	2.41B	1.59B	1.40B	1.45B	1.48B	1.56B	1.30B	1.79B	1.52B	1.30B	1.59B	1.63B	1.50B	1.33B	1.33B	1.18B	1.05B	950.36M	723.84M	559.12M	452.11M	242.80M	163.10M	151.10M	-502.19M
EBITDA Ratio	18.72%	18.31%	29.27%	25.52%	20.45%	18.67%	18.82%	18.10%	20.82%	17.85%	18.42%	20.58%	17.38%	21.43%	22.12%	21.25%	19.88%	21.27%	21.20%	21.07%	19.99%	17.17%	15.37%	13.32%	14.46%	11.66%	13.34%	-31.07%
Operating Income	1.26B	1.43B	2.38B	1.97B	1.23B	1.10B	1.17B	1.28B	1.40B	983.00M	1.48B	1.20B	995.00M	1.30B	1.36B	1.22B	1.09B	1.13B	968.11M	901.44M	795.43M	592.45M	411.39M	317.82M	152.00M	94.30M	74.70M	-601.28M
Operating Income Ratio	13.64%	14.45%	22.07%	20.89%	15.93%	14.62%	15.11%	16.99%	18.67%	13.22%	20.64%	16.27%	13.25%	17.58%	18.23%	16.86%	16.28%	17.99%	17.59%	17.58%	16.79%	14.42%	11.34%	9.29%	6.89%	6.47%	4.89%	-37.20%
Total Other Income/Expenses	-132.00M	-193.00M	218.00M	-87.00M	-155.00M	-175.00M	-135.00M	-142.00M	-101.00M	-134.00M	192.00M	-133.00M	-130.77M	-99.28M	-131.18M	-203.42M	-178.93M	-94.73M	-57.66M	-76.55M	-58.66M	-50.07M	-114.80M	-116.84M	-137.60M	-40.40M	-93.80M	-74.92M
Income Before Tax	1.13B	1.24B	2.60B	1.88B	1.08B	926.00M	1.03B	1.09B	1.10B	849.00M	1.35B	1.07B	856.30M	1.18B	1.23B	1.02B	912.40M	1.03B	910.45M	835.13M	737.80M	542.38M	332.60M	200.98M	14.40M	53.90M	-19.10M	-676.20M
Income Before Tax Ratio	12.21%	12.50%	24.09%	19.96%	13.93%	12.30%	13.36%	14.45%	14.72%	11.42%	18.86%	14.47%	11.40%	16.07%	16.47%	14.06%	13.61%	16.48%	16.54%	16.29%	15.57%	13.20%	9.17%	5.87%	0.65%	3.70%	-1.25%	-41.84%
Income Tax Expense	248.00M	264.00M	597.00M	460.00M	247.00M	182.00M	241.00M	429.00M	373.00M	262.00M	500.00M	401.90M	349.00M	425.50M	460.40M	386.80M	358.57M	407.58M	364.18M	335.93M	301.08M	220.22M	148.69M	96.03M	15.70M	27.00M	3.20M	-50.24M
Net Income	854.00M	946.00M	2.00B	1.43B	858.00M	736.00M	772.00M	645.00M	709.00M	556.00M	849.00M	555.70M	470.60M	720.90M	729.10M	581.50M	339.94M	586.42M	546.28M	499.20M	436.72M	322.15M	162.30M	102.05M	-3.40M	26.90M	-22.30M	-625.96M
Net Income Ratio	9.23%	9.57%	18.49%	15.16%	11.11%	9.77%	10.01%	8.58%	9.46%	7.48%	11.88%	7.53%	6.27%	9.78%	9.78%	8.02%	5.07%	9.35%	9.93%	9.74%	9.22%	7.84%	4.47%	2.98%	-0.15%	1.84%	-1.46%	-38.73%
EPS	7.59	8.12	15.90	10.68	6.38	5.41	5.63	4.58	4.92	3.83	5.58	3.49	2.95	4.08	3.91	2.99	1.76	2.98	2.71	2.45	2.11	1.67	0.87	0.57	-0.03	0.23	-0.19	-5.33
EPS Diluted	7.52	7.98	15.53	10.52	6.29	5.29	5.50	4.51	4.87	3.81	5.54	3.46	2.92	4.05	3.87	2.97	1.74	2.94	2.66	2.35	2.02	1.62	0.83	0.54	-0.03	0.22	-0.19	-5.33
Weighted Avg Shares Out	112.00M	116.00M	125.00M	134.00M	134.00M	136.00M	137.00M	140.00M	144.00M	145.00M	152.00M	158.60M	158.70M	175.70M	185.90M	194.30M	193.24M	196.99M	201.83M	203.75M	206.97M	192.91M	186.56M	179.04M	136.00M	119.56M	115.84M	117.45M
Weighted Avg Shares Out (Dil)	113.00M	118.00M	128.00M	136.00M	136.00M	139.00M	140.00M	142.00M	145.00M	145.00M	153.00M	160.10M	160.20M	177.30M	187.80M	196.00M	195.26M	199.54M	205.53M	212.42M	216.20M	199.48M	195.55M	188.99M	136.00M	120.90M	116.15M	117.45M

Should You Add Quest Diagnostics Stock to Your Portfolio Right Now?

October 9, 2024zacks.com

DGX's strength in Advanced Diagnostics and robust base business volumes are encouraging.

Is Quest Diagnostics (DGX) Stock Undervalued Right Now?

September 30, 2024zacks.com

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...

Quest Diagnostics to Release Third Quarter 2024 Financial Results on October 22, 2024

September 25, 2024prnewswire.com

SECAUCUS, N.J. , Sept. 25, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report third quarter 2024 financial results on Tuesday, October 22, 2024, before the market opens.

Quest Diagnostics Stock Gains From New Offerings, Customer Wins

September 25, 2024zacks.com

A key driver in Brain Health growth is Quest Diagnostics' Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF tests.

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

September 24, 2024zacks.com

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

DGX Stock to Benefit From New Partnership With Sentara Health Plans

September 20, 2024zacks.com

Quest Diagnostics extends services in Virginia and Florida via a partnership with Sentara Health Plans.

Sentara Health Plans and Quest Diagnostics Form Strategic Collaboration to Extend Lab Access in Parts of the Southeast

September 18, 2024prnewswire.com

Quest named exclusive independent lab provider for all Sentara Health Plans in Virginia and Florida SECAUCUS, N.J and HAMPTON ROADS, Va. , Sept. 18, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and...